aTyr Pharma and Kyorin Pharmaceutical Announce Termination of Collaboration Agreement
Key Points of the Termination Agreement
- Collaboration Terminated: aTyr Pharma, Inc. (NASDAQ: LIFE) and Kyorin Pharmaceutical Co., Ltd. have officially terminated their Collaboration and License Agreement, originally signed in January 2020. The agreement termination was initiated by Kyorin, with formal notification provided on May 12, 2026, and the effective termination date set for July 30, 2026.
- Scope: The termination applies not only to the main Collaboration Agreement but also to several ancillary agreements, including Clinical Quality Agreements, Clinical Supply Agreements, and Clinical Study Agreements. The Safety Data Exchange Agreement is set to terminate when Kyorin notifies regulatory authorities of discontinuation of development in its territory.
- Transition & Wind-down: Both parties have outlined comprehensive wind-down activities to ensure a smooth transition. This includes the transfer of critical clinical, regulatory, and intellectual property documents and data from Kyorin to aTyr.
- Licensing & IP Rights: Upon termination, all licenses granted to Kyorin under Section 7.1 of the Collaboration Agreement are revoked. Kyorin grants aTyr a worldwide, irrevocable, perpetual, royalty-free, and fully paid-up license to Kyorin Background Technology and New Kyorin IP, allowing aTyr to develop and commercialize the “Reversion Product” (efatimod) globally. The license on New Kyorin IP is exclusive, even as to Kyorin and its affiliates.
- Orphan Drug Designation: Kyorin will transfer possession and ownership of the orphan drug designation for efatimod in Japan to aTyr, who will secure an In-Country Clinical Caretaker for regulatory purposes.
- Document Transfer: Kyorin will transfer all relevant clinical, regulatory, and trial documentation listed in two schedules (Handover Documents and Essential Documents) to aTyr. These include detailed study reports, regulatory filings, investigator brochures, monitoring plans, and more.
- Regulatory Rights: aTyr is granted the right to access, reference, and use all regulatory filings and materials submitted by Kyorin for efatimod, with this right surviving permanently beyond the termination date.
- Ongoing Responsibilities: Kyorin will continue to act as sponsor for Phase 1 and Phase 3 studies in Japan for archiving clinical documents until regulatory periods expire, then transfer this responsibility to aTyr.
- No Outstanding Payments: The agreement confirms that there are no outstanding payments from Kyorin to aTyr for development costs.
- Legal Framework: The agreement is governed under Swiss law and disputes will be arbitrated per the original collaboration terms.
- Mutual Release: Both parties fully release each other from any claims relating to the Collaboration Agreement prior to the Termination Date, except for breaches of the termination agreement or surviving provisions.
- Disclosure & Integrity: Kyorin warrants full disclosure of all material technical, clinical, and proprietary information needed for aTyr to continue the development and commercialization of efatimod. Both parties commit to executing necessary documents and actions to effectuate the transition.
Potentially Price Sensitive Information for Shareholders
- Loss of Japanese Partner: Kyorin’s exit and termination of the collaboration may impact aTyr’s future commercial prospects in Japan and potentially reduce near-term revenues or milestone payments, depending on prior expectations.
- Transition of Orphan Drug Designation & Regulatory Assets: The transfer of orphan drug designation and regulatory documents may enable aTyr to independently pursue further development and commercialization activities in Japan or seek alternate partners, which could be viewed positively or negatively based on execution risk.
- Access to IP and Regulatory Filings: aTyr now holds exclusive rights to New Kyorin IP and regulatory filings, strengthening its global position for efatimod. This could support ongoing or new business development efforts.
- No Outstanding Liabilities: Confirmation that no outstanding payments are due from Kyorin reduces financial uncertainty.
- Orderly Wind-down and Asset Transfer: The comprehensive transfer of clinical and regulatory documents positions aTyr to continue development activities without disruption, but also places full responsibility for Japanese regulatory compliance and clinical archiving onto aTyr.
- News Release Policy: Both companies will coordinate public disclosures, which may indicate upcoming press releases or investor communications about the termination and transition.
Detailed Schedule of Handover and Essential Documents
The agreement includes exhaustive lists of clinical study documents, regulatory filings, investigator brochures, pharmacology and pharmacokinetic analysis reports, monitoring plans, statistical analysis plans, and more. These documents are critical for maintaining regulatory compliance and for future development and commercialization efforts. Notably, all Japanese Phase 1 and Phase 3 trial documents, orphan drug designation filings, and clinical trial notifications are included, along with insurance statements, IRB approvals, investigator credentials, and investigational product accountability records.
Investor Takeaways
- The termination of the collaboration agreement with Kyorin marks a significant shift in aTyr Pharma’s operational and strategic landscape for efatimod in Japan. While aTyr retains all rights and access to regulatory and IP assets, it must now navigate Japanese regulatory and clinical responsibilities independently or seek new partners.
- The immediate impact could be perceived as negative due to potential loss of commercial momentum and partner support in Japan, but the long-term outcome will depend on aTyr’s execution and ability to leverage the transferred assets.
- Investors should monitor upcoming disclosures from aTyr and Kyorin regarding further development plans, partnering strategies, or regulatory progress in Japan.
Disclaimer
This article is for informational purposes only and does not constitute investment advice. Investors should consider their own circumstances and consult with professional advisors before making any investment decisions. The content herein is derived from official filings and may contain forward-looking statements subject to risks and uncertainties.
